Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
12:15am, Friday, 05'th Feb 2021
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
The Hanover Insurance Group's (THG) CEO Jack Roche on Q4 2020 Results - Earnings Call Transcript
02:45pm, Thursday, 04'th Feb 2021
The Hanover Insurance Group's (THG) CEO Jack Roche on Q4 2020 Results - Earnings Call Transcript
COVID-19 Test Business Fuels Roche Q4 Sales, Hikes Dividend
07:31am, Thursday, 04'th Feb 2021
Roche Holdings (OTC: RHHBF) reports a fourth-quarter lift driven by double-digit growth in the diagnostics business, propelled by its 15 COVID-19 tests portfolio. However, the main pharmaceuticals bus
Roche CEO says Covid testing demand to remain high in 2021
03:31am, Thursday, 04'th Feb 2021
Roche CEO Severin Schwan discusses the company's full-year 2020 earnings, the pharma giant's Covid-19 tests, and the outlook for the pandemic in 2021.
Roche reports solid results in 2020
01:00am, Thursday, 04'th Feb 2021
Basel, 4 February 2021
Bolt Biotherapeutics Aims For $150 Million U.S. IPO
01:53pm, Tuesday, 02'nd Feb 2021
Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
11:25am, Monday, 01'st Feb 2021
Basel, 01 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accept
Wide-Moat Stocks On Sale - The February 2021 Heat Map
09:40pm, Thursday, 28'th Jan 2021
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).
Roche renews partnership with Sysmex to deliver haematology testing solutions
01:03am, Monday, 25'th Jan 2021
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new framework,
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, TENAYA and LUCERNE, evaluating its investig
AbbVie, Roche, Glaxo Are Experts at Product Launches
06:08pm, Thursday, 21'st Jan 2021
Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecast
Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA
10:32am, Thursday, 21'st Jan 2021
The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.
FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
01:00am, Thursday, 21'st Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com
Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy
01:00am, Monday, 18'th Jan 2021
Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not be possible for shareholders to attend the Annual General Meeting in person owing to the ongo
Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project
02:08pm, Thursday, 14'th Jan 2021
Those are some solid endorsements.
